NATCO extends scope of agreement with Akorn Inc

RELATED NEWS NATCO announces 30% rise in revenues Natco Pharma Q2 net up at Rs 9.76cr Natco Pharma fixes Rs 150 ceiling for buyback ALSO READ See latest News about Natco Pharma See previous management interviews See what other Experts & Brokerages are saying about Natco Pharma Natco Pharma BSE | NSE 13/02/12 Are Mutual Funds betting on Natco Pharma?

NATCO Pharma Limited, Hyderabad  is pleased to announce addition of two

injectable drug products to its existing API Supply and Margin Sharing Agreement with Akorn Inc., USA.  With this agreement, the total number of products covered under the agreement goes up to four.  

 

The two ANDA drug products are indicated for the prevention of nausea and vomiting associated with cancer chemotherapy, and have a combined current market size of approximately $360 million.  Under the API Supply and Margin Sharing Agreement that was  signed in April 2006, NATCO will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the United States and Canada.

 

Sourced From: Natco Pharma Limited